Synonym
Clopimozide; NSC 335305; NSC-335305; NSC335305; R 29764; R-29764; R29764;
IUPAC/Chemical Name
1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-5-chloro-1,3-dihydro-2H-benzo[d]imidazol-2-one
InChi Key
JCZYXTVBWHAWLL-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H28ClF2N3O/c29-21-7-12-27-26(18-21)32-28(35)34(27)24-13-16-33(17-14-24)15-1-2-25(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24-25H,1-2,13-17H2,(H,32,35)
SMILES Code
O=C1NC2=CC(Cl)=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
495.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: De Cuyper HJ, Van Praag HM, Mulder WR. Therapeutical significance of clopimozide in the treatment of chronic psychotic patients. Acta Psychiatr Scand. 1979 May;59(5):561-74. PubMed PMID: 37697.
2: Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series. Arzneimittelforschung. 1975 Aug;25(8):1287-94. PubMed PMID: 1242360.
3: Floru L, Tegeler J. Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764). Arzneimittelforschung. 1978;28(2):341-4. PubMed PMID: 25071.
4: Knapen J, Bollen J, Brugmanns J, Rombaut N. [Treatment of chronic psychoses with oral clopimozide]. Acta Psychiatr Belg. 1976 Jul-Aug;76(4):644-57. French. PubMed PMID: 798469.
5: Bobon J, Parent M, Toussaint C, Pinchard A. [Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)]. Acta Psychiatr Belg. 1976 Jan-Feb;76(1):138-43. French. PubMed PMID: 970182.
6: Gould RJ, Murphy KM, Reynolds IJ, Snyder SH. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A. 1983 Aug;80(16):5122-5. PubMed PMID: 6136040; PubMed Central PMCID: PMC384201.
7: Mixon T, Fitzsimmons P. Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results. J Invasive Cardiol. 2006 Jun;18(6):E166-8. PubMed PMID: 16775892.
8: Qar J, Galizzi JP, Fosset M, Lazdunski M. Receptors for diphenylbutylpiperidine neuroleptics in brain, cardiac, and smooth muscle membranes. Relationship with receptors for 1,4-dihydropyridines and phenylalkylamines and with Ca2+ channel blockade. Eur J Pharmacol. 1987 Sep 11;141(2):261-8. PubMed PMID: 2445589.
